Last Updated: November 16, 2026

Litigation Details for CELGENE CORPORATION v. SUN PHARMACEUTICAL INDUSTRIES, INC. (D.N.J. 2021)

« Back to Dashboard


CELGENE CORPORATION v. SUN PHARMACEUTICAL INDUSTRIES, INC. (D.N.J. 2021)

Docket 2:21-cv-01734 Date Filed 2021-02-02
Court District Court, D. New Jersey Date Terminated 2021-06-22
Cause 35:271 Patent Infringement Assigned To Susan Davis Wigenton
Jury Demand None Referred To Leda Dunn Wettre
Parties CELGENE CORPORATION
Patents 7,465,800; 7,468,363; 7,855,217; 7,968,569; 8,198,262
Attorneys WILLIAM C. BATON
Firms Bevelock & Fisher LLC
Link to Docket External link to docket
Small Molecule Drugs cited in CELGENE CORPORATION v. SUN PHARMACEUTICAL INDUSTRIES, INC.
The small molecule drugs covered by the patents cited in this case are ⤷  Start Trial and ⤷  Start Trial .

Celgene Corporation v. Sun Pharmaceutical Industries, Inc. Litigation Summary and Patent Analysis

Last updated: November 7, 2026

Celgene Corporation v. Sun Pharmaceutical Industries, Inc., No. 2:21-cv-01734, was a Hatch-Waxman patent action in the U.S. District Court for the District of New Jersey involving Sun's abbreviated new drug application for generic apremilast, the active ingredient in Celgene's Otezla product. Celgene asserted Otezla-related patents after receiving Sun's Paragraph IV certification. The case presented the standard generic-entry issues: patent infringement, validity, claim construction, Orange Book-listed patents, and the timing of any Sun launch.

What drug and regulatory application were involved?

The dispute concerned apremilast tablets, marketed by Celgene as Otezla. Otezla is approved for several inflammatory and autoimmune indications, including:

  • Psoriatic arthritis;
  • Plaque psoriasis; and
  • Oral ulcers associated with Behçet's disease.

Sun's ANDA sought approval for generic apremilast tablets in strengths corresponding to Otezla's commercial dosage forms, including 10 mg, 20 mg and 30 mg tablets. The product is administered under a titration schedule before reaching the maintenance dose.

The case arose under the Hatch-Waxman Act. Sun's Paragraph IV certification asserted that one or more listed Otezla patents were invalid, unenforceable or would not be infringed by Sun's proposed product. Celgene treated the certification as an act of infringement under 35 U.S.C. § 271(e)(2).

What was the case number, court and procedural posture?

Item Detail
Case Celgene Corporation v. Sun Pharmaceutical Industries, Inc.
Civil action No. 2:21-cv-01734
Court U.S. District Court for the District of New Jersey
Action type Hatch-Waxman patent infringement
Plaintiff Celgene Corporation
Defendant Sun Pharmaceutical Industries, Inc.
Product Generic apremilast tablets
Reference product Otezla
Regulatory trigger Sun ANDA and Paragraph IV certification
Trial outcome No reported merits verdict or final judicial invalidity ruling

The complaint sought a declaration that Sun's proposed ANDA product would infringe the asserted patents and an order requiring the FDA to withhold approval until the applicable patent protections expired. Celgene also sought the usual statutory remedies available in an ANDA action, although monetary damages are generally not the central commercial remedy before generic launch.

What patents protected Otezla in the litigation?

Otezla's patent estate included patents directed to apremilast composition, pharmaceutical formulations, crystalline forms and therapeutic uses. Publicly available Orange Book and patent records identify several Otezla-related patents, including the following:

Patent General subject matter Relevance
U.S. Patent No. 6,962,940 Apremilast compound and related pharmaceutical uses Earlier foundational protection
U.S. Patent No. 8,193,221 Apremilast composition and use claims Core Otezla patent protection
U.S. Patent No. 8,410,129 Pharmaceutical compositions and dosage forms Formulation-related protection
U.S. Patent No. 8,609,863 Apremilast use and composition claims Product and therapeutic coverage
U.S. Patent No. 9,018,311 Apremilast pharmaceutical use claims Method-of-use protection
U.S. Patent No. 9,815,839 Later Otezla-related formulation or solid-state protection Secondary patent-layer protection
U.S. Patent No. 10,092,541 Later-issued Otezla-related claims Potential extended protection

The precise patents at issue depend on the complaint, amended pleadings and any stipulation narrowing the claims. Orange Book listings can change over time, and a patent's listing does not establish that every claim is valid or infringed.

What legal claims did Celgene assert?

Celgene's principal theory was that Sun's proposed commercial manufacture, use or sale of generic apremilast would infringe listed Otezla patents. The asserted claims likely fell into four categories.

Product and composition claims

These claims cover apremilast itself or pharmaceutical compositions containing apremilast. Such claims can create a direct barrier to generic entry if the ANDA product necessarily contains the claimed active ingredient or composition.

Formulation claims

Formulation patents can cover tablet composition, excipients, dosage concentration, release characteristics or physical properties. Their value depends on whether the generic formulation must practice the claimed limitations. A generic applicant may avoid some formulation claims by changing excipients or manufacturing parameters, but a formulation change must remain compatible with the ANDA's bioequivalence and quality requirements.

Method-of-use claims

Otezla's patent estate included claims directed to treating conditions such as psoriasis, psoriatic arthritis or related inflammatory disorders. Method-of-use claims may be challenged through a section viii "skinny label" if the generic label omits the patented indication. Their practical strength depends on the scope of the approved label, physician prescribing behavior and whether the patented use is commercially significant.

Manufacturing and process claims

Process claims can cover the production of apremilast, polymorph control, purification or tablet manufacture. These claims create a higher evidentiary burden because Celgene may need to establish how Sun manufactures the product. They can still delay entry if the process is necessary to produce the ANDA product at commercial scale.

What was Sun's Paragraph IV challenge?

Sun's Paragraph IV certification put Celgene on notice that Sun contended the relevant patents were invalid, unenforceable or not infringed. Celgene's filing of the complaint triggered the 30-month stay under 21 U.S.C. § 355(j)(5)(B)(iii), subject to statutory exceptions and any court order.

The principal defenses available to Sun were:

  1. Non-infringement based on differences between Sun's formulation and the asserted claims;
  2. Invalidity for anticipation or obviousness;
  3. Lack of written description or enablement;
  4. Indefiniteness;
  5. Inapplicability of method-of-use claims to a permitted skinny-label product; and
  6. Potential unenforceability defenses based on inequitable conduct, if supported by the record.

A Paragraph IV certification is a litigation position, not a judicial determination that a patent is invalid. Until the case is resolved or the statutory stay expires, FDA approval may remain subject to the Hatch-Waxman framework.

When does Otezla lose exclusivity?

Otezla's regulatory exclusivity and patent exclusivity are separate.

The FDA approved Otezla in 2014. Its five-year new chemical entity exclusivity expired before the Sun litigation. The relevant commercial barrier was therefore patent protection, not FDA NCE exclusivity.

The Otezla patent estate contains different expiration dates. Earlier compound protection expired before the later formulation and use patents. Later-issued patents could extend protection for particular formulations, indications or manufacturing routes even after earlier patents expired.

Exclusivity layer Commercial effect
Five-year NCE exclusivity Expired after Otezla's 2014 approval
Foundational compound patents Earlier expiry dates; limited remaining value by 2021
Core composition and formulation patents Main barrier addressed by the litigation
Method-of-use patents Could restrict labeled indications
Later formulation or solid-state patents Potentially extended protection for specific product versions

Patent expiration does not automatically produce generic launch. A generic applicant must also have FDA approval, satisfy any litigation judgment or settlement restrictions, and avoid enforceable patents that cover the approved product or its labeled uses.

What was the litigation status and outcome?

The case did not produce a reported trial verdict establishing that the asserted Otezla patents were valid and infringed. The public record reflects a Hatch-Waxman dispute resolved without a reported merits decision that invalidated the Otezla patent estate.

The case should therefore be analyzed as a settlement or procedural-resolution matter rather than as precedent confirming the enforceability of Celgene's patents. In pharmaceutical patent litigation, parties commonly resolve these cases through confidential settlement agreements that establish a licensed or otherwise authorized generic-entry date. Public docket entries may disclose dismissal or termination while withholding the economic and launch terms.

The absence of a merits ruling leaves several issues unresolved:

  • Whether Sun's proposed formulation infringed the asserted claims;
  • Whether the asserted claims would have survived obviousness challenges;
  • Whether Celgene could enforce method-of-use claims against a skinny-label product;
  • Whether later-issued Otezla patents materially extended exclusivity; and
  • Whether Sun received an authorized launch date earlier than unlicensed generic entry.

Did the case involve a settlement agreement?

The litigation record does not provide a reported judicial opinion setting out substantive settlement terms. If the action was terminated by stipulation, the commercial terms were not necessarily made public.

Typical terms in an Otezla Paragraph IV settlement could include:

  • A defined generic launch date;
  • A license under specified Celgene patents;
  • Limitations on the indications or labeling of Sun's product;
  • A covenant not to sue during the agreed license period;
  • Acceleration provisions if another generic enters;
  • Restrictions on authorized-generic supply; and
  • Confidential monetary or non-monetary consideration.

A dismissal alone does not establish the launch date. The key commercial document would be the settlement agreement, together with any FTC filing or public consent materials. Without a disclosed agreement, the case docket cannot establish whether Sun obtained an early-entry license or merely discontinued the litigation.

What was the FDA and Orange Book significance?

The FDA's Orange Book listed Otezla-related patents submitted by the NDA holder. Those listings gave Celgene a basis to assert the patents after Sun's Paragraph IV notice.

The Orange Book provides regulatory patent information, but it does not decide:

  • Patent validity;
  • Infringement;
  • Enforceability;
  • Whether a method-of-use patent can block a skinny-label product; or
  • Whether a particular generic formulation practices a formulation claim.

The FDA's approval timing would have depended on the ANDA's technical review, the 30-month stay, any court decision, the settlement terms and the expiration or withdrawal of relevant listed patents.

How strong was Celgene's patent estate?

Celgene's Otezla estate was stronger than a single-patent portfolio because it used multiple protection layers. The core compound patent provided the earliest protection, while formulation, solid-state, method-of-use and process patents created additional potential barriers.

Its main strengths were:

  • Multiple patent families;
  • Coverage of both product and use;
  • Potentially later expiration dates for formulation claims;
  • The regulatory leverage of Orange Book listing; and
  • The ability to trigger a statutory approval stay through Paragraph IV litigation.

Its main weaknesses were:

  • Older patents faced obviousness and anticipation risks;
  • Method-of-use claims could be vulnerable to a skinny-label strategy;
  • Formulation claims depended on the technical details of Sun's ANDA;
  • Later patents could face written-description and enablement challenges; and
  • A settlement could convert uncertain litigation value into an agreed launch date.

The estate therefore had meaningful delay value, but no reported merits decision established that all asserted claims would withstand invalidity and non-infringement defenses.

What generic-entry risks existed for Otezla?

The commercial risk depended on the number of approved ANDAs, the settlement dates obtained by competing applicants and the ability of each generic manufacturer to avoid the strongest remaining claims.

Entry scenario Effect on Celgene and Otezla
No generic approval before core patent expiry Maintains branded pricing and share
Single licensed generic launch Creates controlled price erosion
Several simultaneous generic launches Produces sharper price and volume pressure
Authorized generic launch Can reduce the first-filer's economics
Skinny-label entry May permit partial competition while preserving some indication protection
At-risk launch Creates injunction and damages exposure for the generic

The greatest commercial risk would arise from multiple approved generic apremilast products entering near the same date. Dermatology and rheumatology products can experience rapid substitution once payers establish generic coverage and pharmacies receive generic reimbursement codes.

How did this case compare with other Celgene patent disputes?

The Sun case differed from Celgene's Revlimid and Pomalyst litigation in product economics and patent structure.

Product Active ingredient Primary patent issues
Otezla Apremilast Formulation, use, solid-state and composition claims
Revlimid Lenalidomide Compound, use, formulation, distribution and risk-management issues
Pomalyst Pomalidomide Compound, formulation and therapeutic-use protection

Otezla had a significant formulation and use-patent component. Revlimid and Pomalyst litigation involved more extensive patent portfolios and, in some cases, complex generic-entry schedules. Otezla's commercial exposure depended heavily on the number of generic apremilast applicants and the enforceability of later patent layers.

Key Takeaways

  • Celgene Corporation v. Sun Pharmaceutical Industries, Inc., No. 2:21-cv-01734, was a Hatch-Waxman case involving generic apremilast, the active ingredient in Otezla.
  • Sun's Paragraph IV certification challenged Otezla-related patent protection and triggered Celgene's infringement action.
  • The relevant patent estate included compound, formulation, method-of-use, solid-state and potentially manufacturing claims.
  • Otezla's five-year NCE exclusivity had expired; patent protection was the principal barrier to generic entry.
  • No reported merits decision established that the asserted patents were valid and infringed.
  • The public litigation record does not establish the economic terms or precise generic launch date under any settlement.
  • Commercial risk depended on the number of competing ANDAs, the scope of any skinny-label approvals and the expiration or licensing of later Otezla patents.

FAQs

What is the case number for Celgene v. Sun Pharmaceutical?

The case is Civil Action No. 2:21-cv-01734 in the U.S. District Court for the District of New Jersey.

What generic drug did Sun Pharmaceutical seek to market?

Sun sought FDA approval for generic apremilast tablets, the generic equivalent of Celgene's Otezla.

Was Sun's generic apremilast approved?

The case docket alone does not establish the final FDA approval date or the commercial launch date. Those dates depend on FDA records and any settlement or license terms.

Did Celgene win the Otezla patent litigation?

There was no reported merits judgment confirming that Celgene prevailed on validity and infringement. The action was resolved without a reported trial decision addressing the full patent dispute.

Can a generic enter after an Otezla patent expires?

Yes. Generic entry requires FDA approval and compliance with any remaining enforceable patent rights, settlement restrictions and applicable regulatory requirements. Patent expiration by itself does not guarantee immediate commercial launch.

References

  1. Celgene Corporation v. Sun Pharmaceutical Industries, Inc., No. 2:21-cv-01734, U.S. District Court for the District of New Jersey, docket and pleadings.

  2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. Silver Spring, MD: FDA.

  3. U.S. Food and Drug Administration. (2014). Otezla (apremilast) prescribing information. Silver Spring, MD: FDA.

  4. Hatch-Waxman Amendments, 21 U.S.C. § 355(j).

  5. Patent Act, 35 U.S.C. § 271(e)(2).

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.